Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-07 pm EST
111.31 USD   -0.78%
02/07Biomarin To Host Fourth Quarter And Full-year 2022 Financial Results Conference Call And Webcast On Monday, February 27, At 4 : 30 p.m. ET
PR
02/03SVB Securities Adjusts BioMarin Pharmaceutical's Price Target to $130 From $122, Maintains Outperform Rating
MT
01/30BMO Capital Initiates BioMarin Pharmaceutical at Market Perform With $107 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

FDA OKs BioMarin's Voxzogo for Children With Most Common Form of Dwarfism

11/19/2021 | 11:00am EST

By Colin Kellaher

The U.S. Food and Drug Administration on Friday said it approved BioMarin Pharmaceutical Inc.'s Voxzogo injection to treat children with the most common form of dwarfism.

The agency said the approval covers Voxzogo to improve growth in children five years of age and older with achondroplasia and open epiphyses, meaning those patients still have the potential to grow.

The FDA said Voxzogo is the first drug approved in the U.S. to treat achondroplasia, a genetic condition that causes severely short stature and disproportionate growth.

The FDA said it gave the green light to Voxzogo under its accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need. The agency said it is requiring a post-marketing study assessing final adult height as a condition of the accelerated approval.

BioMarin, a San Rafael, Calif., biotechnology company, in August said the European Commission approved Voxzogo for the treatment of children from the age of two until growth plates are closed, which occurs after puberty when children reach final adult height.

Shares of BioMarin were recently up 5.4% to $87.37.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

11-19-21 1100ET

All news about BIOMARIN PHARMACEUTICAL INC.
02/07Biomarin To Host Fourth Quarter And : 30 p.m. ET
PR
02/03SVB Securities Adjusts BioMarin Pharmaceutical's Price Target to $130 From $122, Mainta..
MT
01/30BMO Capital Initiates BioMarin Pharmaceutical at Market Perform With $107 Price Target
MT
01/24Morgan Stanley Raises Price Target on BioMarin Pharmaceutical to $132 From $113, Mainta..
MT
01/19Insider Sell: Biomarin Pharmaceutical
MT
01/11Wedbush Raises BioMarin Pharmaceutical's Price Target to $83 From $74 After Model Adjus..
MT
01/09Transcript : BioMarin Pharmaceutical Inc. Presents at 41st Annual J.P. Morgan..
CI
01/09BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN in Largest..
AQ
01/08BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in ..
PR
01/08Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for ..
CI
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 2 095 M - -
Net income 2022 130 M - -
Net cash 2022 304 M - -
P/E ratio 2022 164x
Yield 2022 -
Capitalization 20 687 M 20 687 M -
EV / Sales 2022 9,73x
EV / Sales 2023 7,77x
Nbr of Employees 3 045
Free-Float 99,3%
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 111,31 $
Average target price 122,30 $
Spread / Average Target 9,88%
EPS Revisions
Managers and Directors
Jean-Jacques BienaimÚ Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive VP-Finance
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. von Pervieux Chief Information Officer
C. Greg Guyer Chief Technical Officer & Executive Vice President
Sector and Competitors